Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.61 (
caspase-8
)
6,833
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cancer tissues consist of cancer cells, surrounding stromal cells and the extracellular matrix. Cancer-associated fibroblasts (CAF) are one of the key components of stromal cells. CAF have a great impact on the behavior of cancer cells, including proliferation, invasion, metastasis and chemoresistance in many ways. However, the underlying mechanism had not been fully elucidated. In this study, we investigated the role of CAF in cisplatin resistance of lung cancer cells. By using conditioned medium from CAF (CAF-CM), we found that CAF decreased the sensitivity of lung cancer cells to cisplatin. RNA sequencing results showed that CAF expressed a higher level of
Annexin A3
(
ANXA3
) than normal fibroblasts (NF), and CAF-CM incubation increased the
ANXA3
level in lung cancer cells. Overexpression of
ANXA3
in lung cancer cells increased cisplatin resistance and activated c-jun N-terminal kinase (JNK), whereas knockdown of
ANXA3
increased cisplatin sensitivity. Further study showed that CAF-CM enhanced cisplatin resistance by inhibiting cisplatin-induced apoptosis, determined by repression of caspase-3 and
caspase-8
, through activation of the
ANXA3
/JNK pathway. Conversely, suppression of JNK activation by specific inhibitor retarded the effect of CAF-CM and
ANXA3
on cisplatin sensitivity. Taken together, our study demonstrated that CAF potentiated chemoresistance of lung cancer cells through a novel
ANXA3
/JNK pathway both in vitro and in vivo, suggesting
ANXA3
could be a potential therapeutic target for the treatment of chemoresistant cancer.
...
PMID:Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. 3086 75